EXAS—It took a long time, but Cologuard has finally gone mainstream. There's no longer any reason why normal-risk individuals should be screened with a colonoscopy as the first-line diagnostic for CRC.
For EXAS investors, the ride hasn't been that good, however; the company needed considerable time to grow into its fairly lofty valuation.
News 
Market Data 
Discover 
AI
